Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance

Xinlin Jiao, Siying Zhang, Jun Jiao, Teng Zhang, Wenjie Qu, Guy Muloye, Beihua Kong, Qing Zhang, Baoxia CuiClinical 2019 · DOI

Abstract

These findings provide evidence that SEPT9 methylation could serve as a robust biomarker for cervical cancer diagnosis. SEPT9 promotes tumorigenesis and radioresistance in cervical cancer by targeting the HMGB1-RB axis and inducing the polarization of macrophages through the mediation of miR-375. Consequently, SEPT9 is suggested as a potential screening and therapeutic biomarker for cervical cancer.

Introduction

Cervical cancer remains a leading cause of mortality among women globally. Despite the success of cytology and HPV testing in reducing incidence, these methods face a persistent trade-off between sensitivity and specificity. Furthermore, for patients with invasive cancer, radiotherapy is a primary treatment modality, yet many develop radioresistance, leading to poor clinical outcomes. There is an urgent need for molecular biomarkers that can both detect cancer early and predict therapeutic response.

Methods

The study employed a multi-disciplinary approach to bridge genomic observations with biological mechanisms:

  • Genomic Screening: The Illumina Methylation EPIC 850k Beadchip was used to identify differentially methylated regions in cervical tissues.
  • Validation: Methylation-specific PCR (MSP) and qRT-PCR verified SEPT9 levels in 80 clinical tissue samples from Qilu Hospital.
  • Functional Assays: Proliferation, migration, and cell cycle assays were performed on HeLa and CaSki cell lines.
  • Mechanistic Discovery: LC-MS/MS and co-immunoprecipitation (CoIP) identified proteins interacting with SEPT9.
  • Microenvironment Analysis: Immunofluorescence and Western Blotting tracked the polarization of tumor-associated macrophages (TAMs).
  • In Vivo Validation: Nude mice models were utilized to test tumor growth and response to X-ray irradiation.

Mechanistic Insights: The SEPT9 Paradox

Interestingly, the research identifies a "SEPT9 Paradox": while the SEPT9 promoter is hyper-methylated—a signal typically associated with gene silencing—the mRNA and protein levels are actually upregulated in cancer tissues. This suggests SEPT9 acts as an oncogene in this context.

The HMGB1-RB Axis and Radioresistance

SEPT9 physically interacts with HMGB1, preventing the phosphorylation of the Retinoblastoma (RB) protein. Because RB normally acts as a "brake" on the cell cycle, this interaction accelerates cell division and confers resistance to DNA damage induced by radiation.

Microenvironment Modulation

SEPT9 also communicates with the tumor microenvironment by mediating the downregulation of miR-375. This microRNA is transferred to macrophages, triggering a shift toward the M2 phenotype (pro-tumor/immunosuppressive), which further shields the tumor from the effects of radiotherapy.

Key Results

Diagnostic Accuracy

SEPT9 methylation demonstrated high accuracy in clinical specimens. It distinguished cancer from normal tissue with an AUC of 0.854. When comparing high-grade lesions (CIN2+) and cancer against normal or low-grade tissue, the AUC was 0.797.

ROC curves showing the diagnostic performance of SEPT9 methylation in distinguishing cervical cancer (B) and high-grade lesions (C).

Cellular and In Vivo Impact

In mouse models, SEPT9-overexpressing tumors (SEPT9-LV) were significantly larger following irradiation compared to controls. At the cellular level, knocking down SEPT9 (siSEPT9) led to a significant increase in γH2AX accumulation, a marker of DNA double-strand breaks, proving that SEPT9 helps cancer cells bypass radiation-induced damage.

Discussion and Future Directions

While SEPT9 shows great promise as a screening tool, the clinical cohort was limited to 80 cases from a single institution. Larger, multi-center prospective studies are required for clinical validation. Additionally, the specific epigenetic architecture that allows for oncogenic upregulation despite promoter hyper-methylation warrants deeper investigation. Future research should also explore whether targeting SEPT9 with small molecules can effectively sensitize tumors to radiotherapy in a clinical setting.

Summary updated

Abstract

These findings give us the evidence that SEPT9 methylation could be a biomarker for cervical cancer diagnoses. It promotes tumorigenesis and radioresistance of cervical cancer by targeting HMGB1-RB axis and causes polarization of macrophages by mediating miR-375. We suggest SEPT9 could be a potential screening and therapeutic biomarker for cervical cancer.
BibTeX
@inproceedings{jiao2019promoter,
  author = {Xinlin Jiao and Siying Zhang and Jun Jiao and Teng Zhang and Wenjie Qu and Guy Muloye and Beihua Kong and Qing Zhang and Baoxia Cui},
  title = {{Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance}},
  booktitle = {Clinical},
  year = {2019},
  doi = {10.1186/s13148-019-0719-9},
}
Figure